| Name | Title | Contact Details |
|---|
Innovation is the leading provider of Pharmacy Intelligence™ and pharmacy automation to the retail, hospital, government, and mail order pharmacy markets. Our PharmASSIST® suite of pharmacy automation and process optimization solutions enable all types of pharmacies to increase operational efficiency, enhance patient safety, and provide a higher quality of patient care. Leveraging our unparalleled Pharmacy Intelligence, you can optimize your pharmacy fulfillment process, develop a proven ROI, and gain complete confidence in your automation decisions before investing. Innovation is a name we carry proudly. It is what we do and in many ways who we are. For three and a half decades we have been bringing new technology to industry. Our approach is simple. We start by understanding the problem and then apply all of our talent, expertise, and resources to create new and inventive ways to solve them. That is Innovation.
Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech`s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech`s second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD.
Trimel Pharmaceuticals Corporation is a Canadian specialty pharmaceutical company focused on bringing innovative products to market that improve the patient experience and produce strong investor returns. The Corporation holds a licence for the development and marketing rights to certain products utilizing a bioadhesive intranasal gel drug delivery technology platform and owns a novel unit-dose dry powder inhaler/nasal dispersion system (“TriVair™”). The Corporation is focussing its present efforts on the development and application of these technologies for therapeutic categories such as (a) male hypogonadism (“low testosterone” or “Low-T”) and (b) female orgasmic disorder. Additionally, the Corporation owns the Canadian rights to ESTRACE® and is overseeing its distribution and marketing in Canada. The Corporation’s present drug delivery technology platforms are intended to create products that are expected to be innovative, safer, possibly more effective, easier to use and more practical than competitive products on the market.
Pierre Fabre Laboratories is a Saint-Bruno, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.